Aplastic anemia

Section editor transclusions

9 regimens on this page 12 variants on this page

Guidelines

BSH

• 2017: Paediatric amendment to adult BSH Guidelines for aplastic anaemia

Initial therapy

ATG (Horse) & Cyclosporine

Regimen variant #1

Study	Evidence	Comparator	Comparative Efficacy
Scheinberg et al. 2009 (NHLBI 03-H-0193)	Phase 3 (C)	ATG (Horse), Cyclosporine, Sirolimus	Did not meet primary endpoint of hematologic RR
Tichelli et al. 2011 (SAA-G-CSF)	Phase 3 (C)	ATG (Horse), Cyclosporine, G-CSF	Did not meet primary endpoints of EFS/OS
Scheinberg et al. 2011 (NHLBI 06-H-0034)	Phase 3 (C)	ATG (Rabbit) & Cyclosporine	Superior OS

Immunosuppressive therapy

• Antithymocyte globulin, horse ATG (Atgam) 40 mg/kg IV once per day on days 1 to 4
• Cyclosporine A (type not specified) as follows:
  • Starting dose, 12 and older: 5 mg/kg (route not specified) every 12 hours on day 1
  • Starting dose, younger than 12: 7.5 mg/kg (route not specified) every 12 hours on day 1
  • Dose adjusted to keep trough blood level of 200 to 400 ng/ml
  • Duration: at least 6 months; among responders, CsA was tapered after 6 months with a 25% reduction in dose every 3 months for 18 more months, totaling 2 years of oral CsA (per NHLBI 03-H-0193)

Supportive therapy

• Per NHLBI 03-H-0193:
• Prednisone (Sterapred) 1 mg/kg/day PO on days 1 to 10, then tapered over the next week, to prevent serum sickness
• Pentamidine (Nebupent) (dose not specified) once per month for at least 6 months
• Per others:
• Valacyclovir (Valtrex) (dose not specified) once per day

Regimen variant #2

Study	Evidence	Comparator	Comparative Efficacy
Teramura et al. 2007	Phase 3 (C)	ATG (Horse), Cyclosporine, G-CSF	Seems to have inferior hematologic response rate at 6 months

Immunosuppressive therapy

• Horse ATG (Lymphoglobuline; Merieux, Lyon, France) 15 mg/kg IV over 12 hours once per day on days 1 to 5
• Cyclosporine A (type not specified) as follows:
  • Starting dose: 6 mg/kg/day, continued for at least 28 weeks
  • Dose adjusted to keep trough blood level of 150 to 250 ng/ml

Supportive therapy

• Prednisolone (Millipred) to prevent serum sickness, as follows:
  • Days 1 to 9: 1 mg/kg/day PO
  • Days 10 to 15: 0.5 mg/kg/day PO
  • Days 16 to 21: 0.2 mg/kg/day PO

Regimen variant #3

Study	Evidence	Comparator	Comparative Efficacy
Marsh et al. 1999	Phase 3 (E-esc)	Cyclosporine	Seems to have superior ORR

Immunosuppressive therapy

• Horse ATG (Lymphoglobuline; Merieux, Lyon, France) 15 mg/kg IV once per day on days 1 to 5
• Cyclosporine A (type not specified) as follows:
  • Starting dose: 2.5 mg/kg (route not specified) twice per day
  • Dose adjusted to keep trough blood level of 75 to 200 ng/ml
  • Duration: at least 6 months; if blood cell count continued to increase at 6 months, continued at the therapeutic dose until the blood cell count plateaued, then reduced gradually to help prevent a relapse of the aplasia, per individual clinician discretion

Supportive therapy

• Prednisolone (Millipred) to prevent serum sickness, as follows:
  • Days 5 to 13: 1 mg/kg/day PO
  • Days 14 to 20: reduced to zero over one week (tapering schedule not provided)

References

1. Marsh J, Schrezenmeier H, Marin P, Ilhan O, Ljungman P, McCann S, Socie G, Tichelli A, Passweg J, Hows J, Raghavachar A, Locasciulli A, Bacigalupo A. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood. 1999 Apr 1;93(7):2191-5. link to original article contains dosing details in manuscript PubMed
2. Teramura M, Kimura A, Iwase S, Yonemura Y, Nakao S, Urabe A, Omine M, Mizoguchi H. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood. 2007 Sep 15;110(6):1756-61. Epub 2007 May 25. link to original article contains dosing details in manuscript PubMed
3. NHLBI 03-H-0193: Scheinberg P, Wu CO, Nunez O, Scheinberg P, Boss C, Sloand EM, Young NS. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica. 2009 Mar;94(3):348-54. Epub 2009 Jan 30. link to original article contains dosing details in manuscript link to PMC article PubMed
4. SAA-G-CSF: Tichelli A, Schrezenmeier H, Socié G, Marsh J, Bacigalupo A, Dührsen U, Franzke A, Hallek M, Thiel E, Wilhelm M, Höchsmann B, Barrois A, Champion K, Passweg JR; EBMT. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2011 Apr 28;117(17):4434-41. Epub 2011 Jan 13. link to original article PubMed
   1. Update: Tichelli A, Peffault de Latour R, Passweg J, Knol-Bout C, Socié G, Marsh J, Schrezenmeier H, Höchsmann B, Bacigalupo A, Samarasinghe S, Rovó A, Kulasekararaj A, Röth A, Eikema DJ, Bosman P, Bader P, Risitano A, Dufour C; Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation. Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globuline, cyclosporine, with or without G-CSF: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation. Haematologica. 2020 May;105(5):1223-1231. Epub 2019 Oct 3. link to original article link to PMC article PubMed
5. NHLBI 06-H-0034: Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, Young NS. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011 Aug 4;365(5):430-8. link to original article link to PMC article PubMed

ATG (Horse), Cyclosporine, Eltrombopag

Regimen variant #1, with pediatric dosing

Study	Evidence
Townsley et al. 2017 (NHLBI 12-H-0150)	Phase 1/2

Note: This is the eltrombopag dosing used in cohort 3, which had the highest response rate. ATG and CsA dosing was not described in Townsley et al. 2017 but was based on NHLBI 06-H-0034.

Immunosuppressive therapy

• Antithymocyte globulin, horse ATG (Atgam) 40 mg/kg IV once per day on days 1 to 4
• Cyclosporine A (type not specified) as follows:
  • Starting dose, 12 and older: 5 mg/kg (route not specified) every 12 hours
  • Starting dose, younger than 12: 7.5 mg/kg (route not specified) every 12 hours
  • Dose adjusted to keep trough blood level of 200 to 400 ng/ml

Supportive therapy

• Eltrombopag (Promacta) as follows:
  • Patients 2 to 5 years old: 2.5 mg/kg PO once per day
  • Patients 6 to 11 years old: 75 mg PO once per day
  • Patients 12 and older: 150 mg PO once per day
    • East or Southeast Asian participants had a 50% dose reduction
• Pentamidine (Nebupent) (dose not specified) once per month
• Valacyclovir (Valtrex) (dose not specified) once per day

6-month course

Regimen variant #2

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Peffault de Latour et al. 2022 (RACE)	2015-2019	Phase 3 (E-esc)	ATG (horse) & Cyclosporine	Superior CHR at 3 months

Immunosuppressive therapy

• Antithymocyte globulin, horse ATG (Atgam) 40 mg/kg IV once per day on days 1 to 4
• Cyclosporine 5 mg/kg/day, starting on day 1, continued for a minimum of 12 months, then tapered over the next 12 months

Supportive therapy

• Eltrombopag (Promacta) 150 mg PO once per day, started on day 14, continued for at least 3 and up to 6 months

24-month course

References

1. NHLBI 12-H-0150: Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O, Weinstein B, Valdez J, Lotter J, Feng X, Desierto M, Leuva H, Bevans M, Wu C, Larochelle A, Calvo KR, Dunbar CE, Young NS. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017 Apr 20;376(16):1540-1550. link to original article contains partial protocol link to PMC article PubMed NCT01623167
2. RACE: Peffault de Latour R, Kulasekararaj A, Iacobelli S, Terwel SR, Cook R, Griffin M, Halkes CJM, Recher C, Barraco F, Forcade E, Vallejo JC, Drexler B, Mear JB, Smith AE, Angelucci E, Raymakers RAP, de Groot MR, Daguindau E, Nur E, Barcellini W, Russell NH, Terriou L, Iori AP, La Rocca U, Sureda A, Sánchez-Ortega I, Xicoy B, Jarque I, Cavenagh J, Sicre de Fontbrune F, Marotta S, Munir T, Tjon JML, Tavitian S, Praire A, Clement L, Rabian F, Marano L, Hill A, Palmisani E, Muus P, Cacace F, Frieri C, van Lint MT, Passweg JR, Marsh JCW, Socié G, Mufti GJ, Dufour C, Risitano AM; Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. N Engl J Med. 2022 Jan 6;386(1):11-23. link to original article contains dosing details in manuscript PubMed NCT02099747

ATG (Horse), Cyclosporine, Methylprednisolone

Regimen

Study	Evidence	Comparator	Comparative Efficacy
Frickhofen et al. 1991	Phase 3 (E-esc)	ATG & Methylprednisolone	Seems to have superior ORR

Immunosuppressive therapy

• Antithymocyte globulin, horse ATG (Atgam)
• Cyclosporine
• Methylprednisolone (Solumedrol)

References

1. Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavachar A, Vogt HG, Herrmann F, Freund M, Meusers P, Salama A, Heimpel H; German Aplastic Anemia Study Group. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. N Engl J Med. 1991 May 9;324(19):1297-304. link to original article PubMed

ATG (Horse), Cyclosporine, G-CSF

Regimen

Study	Evidence	Comparator	Comparative Efficacy
Teramura et al. 2007	Phase 3 (E-esc)	ATG (Horse) & Cyclosporine	Seems to have superior hematologic response rate at 6 months
Tichelli et al. 2011 (SAA-G-CSF)	Phase 3 (E-esc)	ATG (Horse) & Cyclosporine	Did not meet primary endpoints of EFS/OS

Immunosuppressive therapy

• Horse ATG (Lymphoglobuline; Merieux, Lyon, France) 15 mg/kg IV over 12 hours once per day on days 1 to 5
• Cyclosporine A (type not specified) as follows:
  • Starting dose: 6 mg/kg/day, continued for at least 28 weeks
  • Dose adjusted to keep trough blood level of 150 to 250 ng/ml

Growth factor therapy

• ONE of the following:
  • Filgrastim (Neupogen) as follows:
    • Days 1 to 28: 400 mcg/m² IV once every other day
    • Days 29 to 84: 400 mcg/m² IV once or twice per week
  • Lenograstim (Granocyte) as follows:
    • Days 1 to 28: 50 mcg/kg IV once every other day
    • Days 29 to 84: 50 mcg/kg IV once or twice per week

Supportive therapy

• Prednisolone (Millipred) to prevent serum sickness, as follows:
  • Days 1 to 9: 1 mg/kg/day PO
  • Days 10 to 15: 0.5 mg/kg/day PO
  • Days 16 to 21: 0.2 mg/kg/day PO

References

1. Teramura M, Kimura A, Iwase S, Yonemura Y, Nakao S, Urabe A, Omine M, Mizoguchi H. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood. 2007 Sep 15;110(6):1756-61. Epub 2007 May 25. link to original article contains dosing details in manuscript PubMed
2. SAA-G-CSF: Tichelli A, Schrezenmeier H, Socié G, Marsh J, Bacigalupo A, Dührsen U, Franzke A, Hallek M, Thiel E, Wilhelm M, Höchsmann B, Barrois A, Champion K, Passweg JR; EBMT. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2011 Apr 28;117(17):4434-41. Epub 2011 Jan 13. link to original article PubMed

ATG (Horse), Cyclosporine, Sirolimus

Regimen

Study	Evidence	Comparator	Comparative Efficacy
Scheinberg et al. 2009 (NHLBI 03-H-0193)	Phase 3 (E-switch-ic)	ATG (Horse) & Cyclosporine	Did not meet primary endpoint of hematologic RR

Immunosuppressive therapy

• Antithymocyte globulin, horse ATG (Atgam) 40 mg/kg IV once per day on days 1 to 4
• Cyclosporine A (type not specified) as follows:
  • Starting dose, 12 and older: 5 mg/kg (route not specified) every 12 hours on day 1
  • Starting dose, younger than 12: 7.5 mg/kg (route not specified) every 12 hours on day 1
  • Dose adjusted to keep trough blood level of 200 to 400 ng/ml
  • Duration: 6 months
• Sirolimus (Rapamune) as follows:
  • Starting dose: 2 mg/day (1 mg/m²/day in children less than 40 kg) on day 1
  • Dose adjusted to keep levels between 5 to 15 ng/ml
  • Duration: 6 months

Supportive therapy

• Prednisone (Sterapred) 1 mg/kg/day PO on days 1 to 10, then tapered over the next week, to prevent serum sickness
• Pentamidine (Nebupent) (dose not specified) once per month for at least 6 months
• Valacyclovir (Valtrex) 500 mg PO once per day for at least 8 weeks

References

1. NHLBI 03-H-0193: Scheinberg P, Wu CO, Nunez O, Scheinberg P, Boss C, Sloand EM, Young NS. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica. 2009 Mar;94(3):348-54. Epub 2009 Jan 30. link to original article contains dosing details in manuscript link to PMC article PubMed

ATG (Rabbit) & Cyclosporine

Regimen

Study	Evidence	Comparator	Comparative Efficacy
Scheinberg et al. 2011 (NHLBI 06-H-0034)	Phase 3 (E-switch-ic)	ATG (Horse) & Cyclosporine	Inferior OS

Immunosuppressive therapy

• Antithymocyte globulin, rabbit ATG (Thymoglobulin) 3.5 mg/kg IV once per day on days 1 to 5
• Cyclosporine A (type not specified) as follows:
  • Starting dose, 12 and older: 5 mg/kg (route not specified) every 12 hours
  • Starting dose, younger than 12: 7.5 mg/kg (route not specified) every 12 hours
  • Dose adjusted to keep trough blood level of 200 to 400 ng/ml

Supportive therapy

• Pentamidine (Nebupent) (dose not specified) once per month
• Valacyclovir (Valtrex) (dose not specified) once per day

References

1. NHLBI 06-H-0034: Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, Young NS. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011 Aug 4;365(5):430-8. link to original article link to PMC article PubMed

Cyclosporine monotherapy

Regimen

Study	Evidence	Comparator	Comparative Efficacy
Gluckman et al. 1992	Phase 3 (E-switch-ic)	ATG (Horse) & Prednisone	Did not meet primary endpoint of hematologic RR
Marsh et al. 1999	Phase 3 (C)	ATG (Horse) & Cyclosporine	Seems to have inferior ORR

Immunosuppressive therapy

• Cyclosporine A (type not specified) as follows:
  • Starting dose: 2.5 mg/kg (route not specified) twice per day
  • Dose adjusted to keep trough blood level of 75 to 200 ng/ml
  • Duration: at least 6 months; if blood cell count continued to increase at 6 months, continued at the therapeutic dose until the blood cell count plateaued, then reduced gradually to help prevent a relapse of the aplasia, per individual clinician discretion

Supportive therapy

• Prednisolone (Millipred) to prevent serum sickness, as follows:
  • Days 5 to 13: 1 mg/kg/day PO
  • Days 14 to 20: reduced to zero over one week (tapering schedule not provided)

References

1. Gluckman E, Esperou-Bourdeau H, Baruchel A, Boogaerts M, Briere J, Donadio D, Leverger G, Leporrier M, Reiffers J, Janvier M, Michallet M, Stryckmans P; Cooperative Group on the Treatment of Aplastic Anemia. Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia. Blood. 1992 May 15;79(10):2540-6. link to original article PubMed
2. Marsh J, Schrezenmeier H, Marin P, Ilhan O, Ljungman P, McCann S, Socie G, Tichelli A, Passweg J, Hows J, Raghavachar A, Locasciulli A, Bacigalupo A. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood. 1999 Apr 1;93(7):2191-5. link to original article contains dosing details in manuscript PubMed

Relapsed or refractory

ATG (Rabbit) & Cyclosporine

Regimen

Study	Evidence
Di Bona et al. 1999	Phase 2
Scheinberg et al. 2006	Phase 2

Immunosuppressive therapy

• Antithymocyte globulin, rabbit ATG (Thymoglobulin)
• Cyclosporine A

References

1. Di Bona E, Rodeghiero F, Bruno B, Gabbas A, Foa P, Locasciulli A, Rosanelli C, Camba L, Saracco P, Lippi A, Iori AP, Porta F, De Rossi G, Comotti B, Iacopino P, Dufour C, Bacigalupo A; GITMO. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Br J Haematol. 1999 Nov;107(2):330-4. Erratum in: Br J Haematol 2000 Feb;108(2):461. De Rossi V [corrected to De Rossi G]. link to original article PubMed
2. Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol. 2006 Jun;133(6):622-7. link to original article PubMed

Eltrombopag monotherapy

Regimen

Study	Evidence	Efficacy
Olnes et al. 2012	Phase 2	RR: 44%

Growth factor therapy

• Eltrombopag (Promacta) 50 mg PO once per day, increased by 25 mg every 2 weeks until platelet count greater than 20 x 10⁹/L or maximum of 150 mg per day

Continued indefinitely

References

1. Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, Parikh AR, Soto S, Biancotto A, Feng X, Lozier J, Wu CO, Young NS, Dunbar CE. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012 Jul 5;367(1):11-9. Erratum in: N Engl J Med. 2012 Jul 19;367(3):284. link to original article contains dosing details in manuscript link to PMC article PubMed
   1. Update: Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, Parikh AR, Broder K, Calvo KR, Wu CO, Young NS, Dunbar CE. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014 Mar 20;123(12):1818-25. Epub 2013 Dec 17. link to original article contains dosing details in manuscript link to PMC article PubMed